LSE - Delayed Quote GBp

Arecor Therapeutics plc (AREC.L)

38.00

0.00

(0.00%)

At close: April 25 at 8:36:15 AM GMT+1

Arecor Therapeutics PLC (LSE:AREC) (FY 2024) Earnings Call Highlights: Strategic Advances Amid ...

Arecor Therapeutics PLC (LSE:AREC) reports revenue growth and strategic progress, despite financial challenges and market competition.

GuruFocus.com 3 days ago

^YH206
Arecor Therapeutics Full Year 2024 Earnings: Misses Expectations

Arecor Therapeutics ( LON:AREC ) Full Year 2024 Results Key Financial Results Revenue: UK£5.05m (up 11% from FY 2023...

Simply Wall St. 3 days ago

AREC.L
0.00%
Arecor Therapeutics First Half 2024 Earnings: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023)

Arecor Therapeutics ( LON:AREC ) First Half 2024 Results Key Financial Results Revenue: UK£2.00m (up 20% from 1H 2023...

Simply Wall St. 6 months ago

AREC.L
0.00%
Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 9 months ago

AREC.L
0.00%
At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes

Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMIConfirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lower

GlobeNewswire 10 months ago

AREC.L
0.00%
Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable he

GlobeNewswire 11 months ago

AREC.L
0.00%

Performance Overview

Return	AREC.L	FTSE 100 (^FTSE)
YTD	-48.30%	+2.96%
1-Year	-72.16%	+4.16%
3-Year	-90.26%	+14.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arecor Therapeutics plc (AREC.L)

Arecor Therapeutics PLC (LSE:AREC) (FY 2024) Earnings Call Highlights: Strategic Advances Amid ...

Arecor Therapeutics Full Year 2024 Earnings: Misses Expectations

Arecor Therapeutics First Half 2024 Earnings: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023)

Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Performance Overview